Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Williams Companies Inc (WMB) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Williams Companies IncTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Williams Companies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Williams Companies Inc trades at $73.83 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 17.4× ACADIA Pharmaceuticals Inc.'s market cap, and Williams Companies Inc pays a 2.9% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADWMB
Market Cap
$5.07B$88.45B
Sector
HealthEnergy
52-Week High
$29.41$79.40
52-Week Low
$20.06$56.51
Enterprise Value
$4.19B$119.07B
Dividend Yield
2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

Williams Companies Inc

Williams Companies (WMB) trades at $73.60, up 2.44% with a bullish technical signal despite mixed earnings history. The company reported strong Q1 2026 results but missed Q2 estimates, while raising full-year EBITDA guidance to $8.4 billion. Analyst consensus remains strongly bullish with a $87.14 price target, supported by the recent $5.5 billion Momentum Midstream acquisition that enhances Gulf Coast exposure and supports 11% annual growth targets through 2030.

WMB presents a compelling investment case with strong profitability metrics (25.18% net margin, 24.02% ROE) and dividend stability ($2.10 annualized). Key risks include execution challenges from the Momentum integration, debt levels at 52.07% of assets, and potential volatility from energy market fluctuations. The stock offers 18% upside to consensus target with institutional support despite recent position reductions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Williams Companies Inc

Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.

Read more on WMB